In 1982, hemorrhagic colitis and hemolytic-uremic syndrome were linked to infection with Escherichia coli O157:H7, a serotype now classified as Shiga toxin-producing E. coli (STEC). Thereafter, hemorrhagic colitis and hemolytic-uremic syndrome associated with non-O157 STEC serogroups were reported, with the frequency of non-O157 STEC illness rivaling that of O157:H7 in certain geographic regions. In the United States, non-O157 E. coli may account for up to 20%-50% of all STEC infections. A high index of suspicion, paired with options to test for non-O157 STEC infection, are necessary for early recognition and appropriate treatment of these infections. Supportive care without the use of antibiotics is currently considered to be optimal treatment for all STEC infections. This commentary provides a perspective on the non-O157 STEC as human pathogens, how and when the clinician should approach the diagnosis of these organisms, and the challenges ahead.
In 1982, infection with Shiga toxin-producing Escherichia coli (STEC) O157:H7 strains was linked to hemorrhagic colitis and the hemolytic-uremic syndrome (HUS), defining a new foodborne zoonosis. Since then, ∼250 different O serogroups of E. coli have been shown to produce Shiga toxin, and 1100 of these STEC have been associated with sporadic and epidemic human diarrheal disease. Although the virulence of E. coli O157:H7 is well described, over the past 20 years, the capacity of the heterogeneous family of non-O157 STEC to induce human disease has spurred considerable, even heated, debate [1] [2] [3] . The data, although presented in variable detail, indicate that some non-O157 STEC unequivocally cause human disease and likely account for 20%-50% of STEC infections (an estimated 37,000 cases of illness) annually in the United States [4] . This commentary collates selected data to provide a perspective on the non-O157 STEC as human pathogens, how and when the clinician should approach diagnosis of these organisms, and the challenges ahead. We focused on reports that included у5 patients infected with non-O157 STEC and that provided clinical details of the disease spectrum observed. variability of disease noted with non-O157 STEC may be related to their notable genetic heterogeneity. At least 15 studies help to define the breadth of non-O157 STEC-related illness [1, 6, 9, 13-15, 17, 26, 32, 37, 40-44] (table 2) . Although non-O157 serogroups appear to cause watery diarrheal illness more often than bloody diarrheal illnesses [6, 45] , it is equally apparent that bloody diarrhea associated with STEC infection cannot be presumed to be due to O157 infection. Conversely, O157 infection does not inevitably cause hemorrhagic colitis. A 2-year prospective study of 5415 cases of sporadic diarrhea in Canada revealed significant differences between the clinical syndromes associated with non-O157 and O157 STEC infection [9] . Patients with non-O157 STEC infection had a longer duration of diarrhea (mean duration, 9.1 days vs. 5.7 days; ) and P ! .001 less frequent bloody diarrhea (42% vs. 97%;
). In con-P ! .001 trast, the rate of abdominal pain, vomiting, and fever of 138ЊC did not differ between patients with non-O157 infections and those with O157 infections. In a recent study of 343 Danish patients with STEC infections [26] , serogroups O157 and O103 were independent risk factors for bloody diarrhea on multivariate analysis with indistinguishable ORs and 95% CIs, confirming that certain non-O157 serogroups can be as virulent as O157:H7 strains. The virulence of non-O157 strains is further illustrated by a study of 394 children with HUS in Germany and Austria, in which 57% of children with non-O157 illness and 71% of those with O157 illness presented with bloody diarrhea. Although statistically significant ( ), this differ-P ! .05 ence is clinically meaningless [15] . (55) 8 (16) 18 (37) Clinical data limited, retrospective design Bielaszewska et al. [44] 6 (26) 6 (26) 10 (43) Clinical data limited Huppertz et al. [14] 1996 Prospective study (1994) Hospitalized children and adolescents !16 years old with diarrhea Germany 11/468
11 (100) 2 (18) 1 (9) Well-characterized cohort Beutin et al. [1] 1998 Retrospective multicenter study (1996) Non-O157 isolates from adults and children submitted to a central laboratory (87) 7 (8) 4 (5) Well-characterized cohort Gerber et al. [15] 7 (35) 9 (45) 2 (10) Well-characterized cohort Blanco et al. [17] 2004
Prospective study (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (68) 18 (21) 1 ( (26) 10 (4) Well-characterized cohort Brooks et al. [43] (24) 28 (74) 5 (13) Well-characterized cohort NOTE. Studies are ordered chronologically by publication year. Non-O157 STEC infection was identified by fecal culture and/or a positive result of any of the following tests: cytotoxin neutralizing assay, stx DNA probe assay, or serology. Unless noted, diarrhea is non-bloody. Cases of diarrhea may have been associated with HUS; there is overlap in the cases reported for each clinical category, such that the syndromes of diarrhea (non-bloody vs. bloody) and HUS may have been noted in a single patient. Studies were selected for systematic analysis of STEC strains and reporting of clinical features to demonstrate the spectrum of non-O157 STEC illness. This is intended to provide a global perspective on the diversity of clinical data and serogroup identification. CDC, Centers for Disease Control and Prevention; HUS, hemolytic-uremic syndrome; NR, not reported; NS, not specified.
a When HUS was studied prospectively, data reported are total number of HUS cases/total number of non-O157 STEC infections identified. Asymptomatic cases of infection due to non-O157 STEC were eliminated from the analysis when symptom-free data were provided.
b
Bloody diarrhea was reported only as a percentage of all reported illnesses; thus, we were unable to derive non-O157-associated bloody diarrhea. HUS is a triad of acute renal failure , microangiopathic hemolytic anemia, and thrombocytopenia. In the majority of cases in children, HUS occurs after a diarrheal illness, but bloody diarrhea is not a prerequisite. Worldwide, diarrhea-associated HUS largely accounts for morbidity and mortality due to STEC, resulting in death (in up to 5%) and frequent permanent renal injury (at an estimated rate of 25%) [46] . Because most of the data detailing the risk of progression to HUS, HUS-related mortality, and development of permanent renal injury following HUS have been obtained from O157:H7-associated diarrheal outbreaks, it is unknown whether these data also will be true in diarrheal illness associated with non-O157 strains. However, it is clear that infection with non-O157 strains can result in HUS. In a 4-year study of children and adults with HUS in the United States, 5 (16.7%) of 30 patients had infection due to non-O157 strains [7] . Argentina has the highest global rates of HUS, estimated annually at 12.2 cases per 100,000 [37] among children younger than 5 years, and non-O157 strains account for nearly all of this disease burden [42] . Similar findings are reported from Australia [33] . In Germany and Austria, a prospective evaluation of sporadic cases of HUS in children revealed non-O157 STEC in nearly one-half (43%) of patients studied [47] . Additional studies from Germany, Belgium, Finland, the Czech Republic, and Italy also suggest that the rate of isolation of non-O157 strains exceeds that of O157 strains among patients with diarrhea and HUS in these regions.
Certain non-O157 serotypes, particularly O111, trigger sporadic and outbreak-associated HUS more frequently than other non-O157 STEC. In a recent sampling of 940 non-O157 human isolates sent to the Centers for Disease Control and Prevention (Atlanta, GA) by public health laboratories in 42 states and the District of Columbia from 1983 through 2002, isolates from 21 cases of HUS were identified [43] . Serogroup O111 accounted for 48% of HUS cases, but missing data limited the power of the analysis. In Germany, Austria, and Australia, O111 strains were most frequently associated with HUS [33, 47] . These and other data suggest that infection with serotypes O26, O103, and O145 may also be relatively more likely to precipitate HUS (table 1) .
Although it is not clear whether the pathogenesis of HUS following infection with non-O157 strains exactly mirrors that following infection due to O157 strains, non-O157 strains harboring the gene encoding stx2 (see Disease Pathogenesis: Complex and Evolving) are those most highly associated with onset of HUS, a finding analogous to that for O157 strains. This similarity suggests that some infections due to non-O157 strains trigger the same abnormalities of the clotting cascade that precipitate HUS following infection due to O157 strains [48] . More data are needed to determine whether, for example, peripheral leukocytosis signals a greater probability of HUS, as has been noted in O157-associated disease [49, 50] .
DISEASE PATHOGENESIS: COMPLEX AND EVOLVING
The ability to express one or more subtypes of Shiga toxin defines membership in the STEC family. Production of Shiga toxin is central to the pathogenesis of both O157-and non-O157-associated human disease. Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) are the main members of this toxin family. In contrast to STEC that produce Stx1 only, STEC that produce Stx2 alone or both Stx1 and Stx2 are more likely to be associated with HUS [51] . Of note, intravenous administration of purified Stx2 alone in the baboon model of HUS is sufficient to cause the hallmark pathological features of HUS, at doses at which Stx1 alone will not.
Like cholera toxin and pertussis toxin, the Shiga toxins are members of the AB5 toxin family, consisting of 1 enzymatically active A subunit non-covalently associated with a binding pentamer of identical B subunits. The B subunit binds to neutral glycolipids on host cells and mediates cellular uptake of Shiga toxin with trafficking to the endoplasmic reticulum. In the endoplasmic reticulum, the A subunit is translocated across the endoplasmic reticulum membrane to the cytoplasm, thereby gaining access to cytoplasmic ribosomes. The A subunit recognizes and binds to the 28S RNA portion of the 60S ribosomal subunit and cleaves off a specific adenine, preventing aminoacyl t-RNA binding. This results in inhibition of protein synthesis and can trigger host cell signal transduction mechanisms that may favor expression of proinflammatory cytokines. Therefore, Shiga toxins likely have 2 mechanisms by which they cause local and systemic disease: direct (inhibition of protein synthesis) and indirect (proinflammatory cytokine expression).
Because STEC are noninvasive, Shiga toxins must be absorbed across the intestinal epithelium to gain access to the systemic circulation. It is thought that Shiga toxins, once absorbed, act on a variety of host cell subtypes, including endothelial cells in target organs, such as the kidney and the brain, to cause pathological hallmarks of systemic disease: deposition of fibrin-platelet thrombi in affected tissues. Recent data suggest that there may be additional mediators of cell injury and death, including the secreted zinc metalloprotease of C1 esterase inhibitor [52] , subtilase cytotoxin (SubAB), and cytolethal distending toxin [53] . Thus, the degree to which different strains of STEC may colonize the gastrointestinal tract, cause disruption of the gastrointestinal barrier, and produce Shiga toxin locally may vary (thereby influencing the likelihood of developing HUS) according to strain-dependent encoded and expressed virulence genes.
Virulence characteristics vary among non-O157 strains and likely influence their pathogenicity. STEC strains may carry the locus of enterocyte effacement (LEE), a 43-kb pathogenicity island containing a cluster of genes whose cooperative protein products contribute to STEC pathogenesis. The presence of LEE in non-O157 strains correlates with virulence, because strains containing LEE are more frequently associated with HUS and outbreaks than are LEE-negative strains. Consistent with the increased association between STEC carrying LEE and human disease, serogroups O26, O103, O111, O121, and O145 (all associated with outbreaks of severe disease, including HUS [54] ) are predominantly LEE-positive [38, 54, 55] and cdtnegative strains [56] . These and other data suggest that infection with certain serogroups may be more likely to precipitate HUS (table 3) . LEE contains genes whose expression permits formation of the attaching and effacing lesions characteristic of STEC intestinal colonization. LEE also contains genes that encode a type III secretion system that delivers the proteins mediating the attaching and effacing lesions and other virulence proteins to enterocytes. Attaching and effacing lesions form when LEE-encoded intimin (eae), an outer membrane protein homologue, binds to the translocated intimin receptor (tir) that inserts into the enterocyte membrane-a unique example of a pathogen providing to the host the receptor required for its colonization. In a Finnish study of all human non-O157 strains collected over a decade from symptomatic persons, 70% carried the eae gene [29] , 55% carried stx2, and 75% carried E-hly. Ehly encodes enterohemolysin, a pore-forming cytolysin that may be associated with the presence of eae in non-O157 versus O157 strains [29] . The precise contribution of enterohemolysin to STEC virulence remains unknown. However, none of these human isolates lacked all 3 of these virulence genes. In other work, the adherence of STEC to enterocytes (dependent, in part, on the expression of eae) correlated directly with pathogenicity when strains from sporadic and outbreak-associated HUS were compared with isolates from food and from species other than humans [29, 74] . Genes encoding potential virulence factors are found more frequently in non-O157 STEC serogroups isolated from patients with bloody diarrhea and/or HUS than they are from patients with non-O157 STEC-associated nonbloody diarrhea.
The observations that O157 and non-O157 LEE-negative STEC can lead to significant disease in humans led investigators to look for other virulence traits, resulting in the discovery of new pathogenicity islands. Notably, the high-pathogenicity island is unique to certain non-O157 serogroups, such as O26, one of the most frequently reported serogroups in Europe and the United States [75] . The high-pathogenicity island encodes genes required for synthesis of an iron-recruitment system, called yersiniabactin, that is also found in pathogenic Yersinia species and other enterobacteria. Sequencing of the O157 genome identified 8 additional pathogenicity-associated islands that may contribute to strain virulence [76] . Certain non-O157 strains known to cause severe disease in humans carry у1 of these recently recognized pathogenicity islands, but further work is needed to understand the relationship of these islands to both O157-and non-O157-related human disease [54] .
Additional investigation into the determinants of virulence of non-O157 STEC will likely yield exciting results, as illustrated by the recent discovery of a novel AB5 toxin, SubAB, in an Australian STEC O113:H21 strain associated with a small outbreak of HUS [77] . Notably, this strain does not possess the eae gene.
Intraperitoneal injection of purified SubAB is fatal in a murine model, causing microvascular thrombosis and the subsequent necrosis within multiple organs [77] . SubAB genes have been found in fecal extracts from ∼10% of Australian STEC cases and are typically found in STEC that produce only Stx2 [78] . The worldwide distribution of SubAB in both STEC and other E. coli is unknown, and its contribution to strain virulence and disease requires further study.
SCREENING AND ISOLATION OF NON-O157: A DIFFICULT SEARCH
Stool samples for cultures must be obtained early in the disease course to reliably isolate O157, and presumably the same is true for non-O157 strains. O157 strains are easier to detect on stool culture, because most strains fail to metabolize sorbitol. This leads to colorless, opaque-appearing colonies on sorbitolMacConkey agar, rather than the pink colonies (caused by fermentation of sorbitol) typical of most non-O157 STEC, as well as commensal and pathogenic diarrhea-inducing classes of E. coli (e.g., enteropathogenic E. coli and enterotoxigenic E. coli, among others). Thus, given the serogroup diversity of non-O157 STEC, the only practical rapid approach, at present, to identify non-O157 STEC-related disease is direct or indirect detection of Shiga toxin production by these strains. One of 2 EIAs approved by the US Food and Drug Administration to detect Shiga toxin may be performed either directly on stool samples or on supernatants of an overnight enrichment culture of stool [79] . Sensitivity of EIA is enhanced by adding mitomycin C or polymyxin B to stool cultures to stimulate production or liberation of bacterial cellassociated Shiga toxin. Alternatively, a tissue culture cytotoxicity and neutralization assay can detect Shiga toxin, but this reference standard approach is too laborious and costly to be widely adopted for diagnosis. PCR-based methods to detect Shiga toxin genes in diarrheal stools may emerge as a rapid identification method in diagnostic laboratories capable of reliably performing these assays. One limitation of these approaches is that the non-O157 strains are not recovered and characterized. Ultimately, culture remains important for tracking non-O157 disease epidemiology and the development of public health strategies for containment.
Is rapid diagnosis of infection due to non-O157 STEC clinically necessary? Given the severe disease associated with some non-O157 STEC serogroups, rapid diagnostic measures con- firmed by culture are optimal. Although testing all patients with diarrheal syndromes for non-O157 STEC infection is ideal, costs may well be prohibitive in regions in which incidence is low. For this reason, development and investigations of rapid, cost-effective diagnostic methods are imperative. The leading life-threatening sequela of STEC infection is development of HUS. Because the critical pathophysiological changes of HUS are occurring by the time that the patient presents with the diarrheal prodrome, only early interventions-requiring rapid diagnostics-to interrupt coagulation cascade dysregulation will reduce morbidity and mortality caused by HUS. Further, bloody diarrhea is a serious illness among both children and adults, compelling clinicians to consider early, empirical antibiotic therapy. However, current recommendations and available data (although limited in scope and only formally studied for O157-related infections in children) suggest that antibiotics should be withheld if STEC infection is suspected, given concerns that antibiotics may trigger release of Stx and progression to HUS, resulting in worse clinical outcomes. These considerations support an argument for early diagnosis of STEC infection. The case for rapid specific diagnosis of STEC infection is further supported by a recent prospective study of 29 children with O157-associated bloody diarrhea or HUS, which suggests that early isotonic volume expansion-occurring before culture results are available-may attenuate renal injury and failure [80] . The value and potential complications (e.g., volume overload) of aggressive hydration in adults and the benefit in non-O157 STEC infections are unknown and are likely to remain so, indicating that clinicians may well have to take their management cues from these limited data. Thus, rapid diagnosis of all STEC infections should assist clinical decision-making regarding fluid and antibiotic administration. Because the clinical manifestations of STEC infection may mimic appendicitis, intussusception, inflammatory bowel disease, and Clostridium difficile infection, rapid diagnosis may avert both invasive endoscopy procedures, which are costly and carry potential morbidity, and emergent surgical procedures. Finally, rapid diagnosis may serve to limit outbreaks. Clinician-initiated reports of STEC infection to public health authorities will allow timely outbreak investigations that may permit detection of additional STEC cases, limit spread from persistently contaminated common sources, and/or prevent secondary spread within families.
CONCLUSIONS AND RECOMMENDATIONS
Non-O157 STEC infections may induce a range of illness, from mild gastroenteritis to critical illnesses, including hemorrhagic colitis, HUS, and death, either as sporadic cases or in outbreaks, reported in the United States and internationally. A substantial proportion of HUS is caused by infection due to non-O157 strains worldwide, but the true incidence and burden of illness caused by these E. coli serotypes remain unknown. In 2000, only 68% of clinical laboratories in the United States tested routinely for infections due to O157 STEC, with fewer laboratories testing for non-O157 STEC infections [81] . The search for STEC infection should begin, at a minimum, in patients presenting with bloody diarrhea and/or HUS. Ideally, screening for STEC on all stool specimens submitted because of diarrheal illness should be considered, but the cost-effectiveness of this approach, given the geographic variability of both O157 and non-O157 STEC infections, requires assessment. If specific and effective therapies that prevent HUS are developed, the need to diagnose STEC infection will be compelling. Rapid, sensitive, accurate, and inexpensive techniques to enable routine testing for Shiga toxin and non-O157 strains should be developed and incorporated into clinical laboratory protocols. Only through active case investigation will we further understand the distribution and human cost of non-O157-associated disease.
